These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 32943490)

  • 1. Expression of the immunoproteasome subunit β5i in non-small cell lung carcinomas.
    Kiuchi T; Tomaru U; Ishizu A; Imagawa M; Iwasaki S; Suzuki A; Otsuka N; Ohhara Y; Kinoshita I; Matsuno Y; Dosaka-Akita H; Kasahara M
    J Clin Pathol; 2021 May; 74(5):300-306. PubMed ID: 32943490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the immunoproteasome as a potential therapeutic target in cisplatin-resistant small cell and non-small cell lung cancer.
    Shoji T; Kikuchi E; Kikuchi J; Takashima Y; Furuta M; Takahashi H; Tsuji K; Maeda M; Kinoshita I; Dosaka-Akita H; Sakakibara-Konishi J; Konno S
    Cancer Chemother Pharmacol; 2020 May; 85(5):843-853. PubMed ID: 32232513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The immunoproteasomes are key to regulate myokines and MHC class I expression in idiopathic inflammatory myopathies.
    Bhattarai S; Ghannam K; Krause S; Benveniste O; Marg A; de Bruin G; Xin BT; Overkleeft HS; Spuler S; Stenzel W; Feist E
    J Autoimmun; 2016 Dec; 75():118-129. PubMed ID: 27522114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitors.
    Downey-Kopyscinski S; Daily EW; Gautier M; Bhatt A; Florea BI; Mitsiades CS; Richardson PG; Driessen C; Overkleeft HS; Kisselev AF
    Blood Adv; 2018 Oct; 2(19):2443-2451. PubMed ID: 30266819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of N-acetylglucosaminyltransferase v is associated with prognosis and histology in non-small cell lung cancers.
    Dosaka-Akita H; Miyoshi E; Suzuki O; Itoh T; Katoh H; Taniguchi N
    Clin Cancer Res; 2004 Mar; 10(5):1773-9. PubMed ID: 15014031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Cell-Based Platform for the Investigation of Immunoproteasome Subunit β5i Expression and Biology of β5i-Containing Proteasomes.
    Burov A; Funikov S; Vagapova E; Dalina A; Rezvykh A; Shyrokova E; Lebedev T; Grigorieva E; Popenko V; Leonova O; Spasskaya D; Spirin P; Prassolov V; Karpov V; Morozov A
    Cells; 2021 Nov; 10(11):. PubMed ID: 34831272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of N, C-capped di- and tripeptides as selective immunoproteasome inhibitors.
    Nan G; Huang L; Li Y; Yang Y; Yang Y; Li K; Lai F; Chen X; Xiao Z
    Eur J Med Chem; 2022 Apr; 234():114252. PubMed ID: 35286927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibiting the immunoproteasome's β5i catalytic activity affects human peripheral blood-derived immune cell viability.
    Pletinckx K; Vaßen S; Schlusche I; Nordhoff S; Bahrenberg G; Dunkern TR
    Pharmacol Res Perspect; 2019 Aug; 7(4):e00482. PubMed ID: 31236277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methionine Aminopeptidase 2 as a Potential Therapeutic Target for Human Non-Small-Cell Lung Cancers.
    Shimizu H; Yamagishi S; Chiba H; Ghazizadeh M
    Adv Clin Exp Med; 2016; 25(1):117-28. PubMed ID: 26935506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteasome Levels and Activity in Pregnancies Complicated by Severe Preeclampsia and Hemolysis, Elevated Liver Enzymes, and Thrombocytopenia (HELLP) Syndrome.
    Berryman K; Buhimschi CS; Zhao G; Axe M; Locke M; Buhimschi IA
    Hypertension; 2019 Jun; 73(6):1308-1318. PubMed ID: 31067191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virtual Screening Strategy and In Vitro Tests to Identify New Inhibitors of the Immunoproteasome.
    Culletta G; Tutone M; Ettari R; Perricone U; Di Chio C; Almerico AM; Zappalà M
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of peptide epoxyketones as selective immunoproteasome inhibitors.
    Li X; Hong D; Zhang M; Xu L; Zhou Y; Li J; Liu T
    Eur J Med Chem; 2021 Oct; 221():113556. PubMed ID: 34087498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
    Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
    J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome.
    Tripathi SC; Peters HL; Taguchi A; Katayama H; Wang H; Momin A; Jolly MK; Celiktas M; Rodriguez-Canales J; Liu H; Behrens C; Wistuba II; Ben-Jacob E; Levine H; Molldrem JJ; Hanash SM; Ostrin EJ
    Proc Natl Acad Sci U S A; 2016 Mar; 113(11):E1555-64. PubMed ID: 26929325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of fucosyltransferase 8 is associated with an unfavorable clinical outcome in non-small cell lung cancers.
    Honma R; Kinoshita I; Miyoshi E; Tomaru U; Matsuno Y; Shimizu Y; Takeuchi S; Kobayashi Y; Kaga K; Taniguchi N; Dosaka-Akita H
    Oncology; 2015; 88(5):298-308. PubMed ID: 25572677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The immunoproteasome β5i subunit is a key contributor to ictogenesis in a rat model of chronic epilepsy.
    Mishto M; Raza ML; de Biase D; Ravizza T; Vasuri F; Martucci M; Keller C; Bellavista E; Buchholz TJ; Kloetzel PM; Pession A; Vezzani A; Heinemann U
    Brain Behav Immun; 2015 Oct; 49():188-96. PubMed ID: 26044087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma.
    Ettari R; Zappalà M; Grasso S; Musolino C; Innao V; Allegra A
    Pharmacol Ther; 2018 Feb; 182():176-192. PubMed ID: 28911826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I molecules.
    Guillaume B; Chapiro J; Stroobant V; Colau D; Van Holle B; Parvizi G; Bousquet-Dubouch MP; Théate I; Parmentier N; Van den Eynde BJ
    Proc Natl Acad Sci U S A; 2010 Oct; 107(43):18599-604. PubMed ID: 20937868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-Activity Relationships of Noncovalent Immunoproteasome β5i-Selective Dipeptides.
    Zhan W; Singh PK; Ban Y; Qing X; Ah Kioon MD; Fan H; Zhao Q; Wang R; Sukenick G; Salmon J; Warren JD; Ma X; Barrat FJ; Nathan CF; Lin G
    J Med Chem; 2020 Nov; 63(21):13103-13123. PubMed ID: 33095579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoproteasome-specific inhibitors and their application.
    Basler M; Groettrup M
    Methods Mol Biol; 2012; 832():391-401. PubMed ID: 22350900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.